Dabigatran to Prevent Stroke in Patients With Atrial Fibrillation

Summary and conclusions

Atrial fibrillation is the most common type of cardiac arrhythmia. Atrial fibrillation increases the risk of forming blood clots, clots that the circulatory system carries through the body. These clots may cause vascular events such as stroke. To prevent stroke, doctors use drugs that reduce the blood’s ability to coagulate (anticoagulants) when treating many patients who present with atrial fibrillation and at least one additional stroke risk factor. Warfarin is commonly used, but the drug must be carefully managed since it carries a risk for serious bleeding. Dabigatran is a new type of anticoagulant with a different mechanism of action. Dabigatran has been compared to warfarin therapy, and a recently published analysis of the study compares results from four categories of centres where warfarin therapy has been managed with greater or lesser success. Since previous research shows that warfarin therapy is usually managed very well in Sweden, this SBU Alert report is based mainly on study results from the centres that manage warfarin therapy most successfully. Hence, the conclusions of this report are based on the assumption that the quality of warfarin therapy in Sweden will continue to be very well managed. Consequently, follow-up and monitoring of the quality of warfarin therapy is of major importance.

Conclusions from clinical studies are based on comparisons at the group level. Despite the conclusion presented under the first point, there are presumably individuals for whom dabigatran yields a better balance between risks and benefits than warfarin does, eg, patients who have tried warfarin and for whom the dose could not be successfully established.

For patients where warfarin therapy was deemed inappropriate (contraindicated) from the outset, no evidence is available to appraise the benefits and risks of dabigatran.

Given the current price of dabigatran, and based on a comparison of centres with high-quality management of warfarin, warfarin therapy is the most cost-effective option. Since the health economic analysis is sensitive to costs associated with visits for specimen taking, there may be individuals for whom dabigatran is, for various reasons, more cost-effective than warfarin therapy.

SBU’s appraisal of the evidence

An overall appraisal of the medical benefits and risks for the patient group as a whole does not show dabigatran to be superior to warfarin in treating patients with atrial fibrillation and a higher risk of stroke. Assuming that warfarin therapy is well managed, which is the norm in Sweden, dabigatran and warfarin show no substantial differences in risk, either for stroke and other types of blood clots, or for serious haemorrhaging generally or death regardless of cause. The specific risk for cerebral haemorrhage appears, however, to be lower with dabigatran than with warfarin even when warfarin therapy is well managed, but this must be viewed against the potential risks of dabigatran.

Technology and target group

Atrial fibrillation is the most common type of cardiac arrhythmia. The condition is estimated to affect 100 000 people in Sweden, and it is more common at higher ages. Atrial fibrillation is associated with an annual risk for stroke of 3 to 5 percent. Examples of other factors that contribute to further increasing the risk of atrial fibrillation are smoking, hypertension, and diabetes along with other cardiac disorders such as congestive heart failure, angina, and cardiomyopathy.

Vitamin K antagonists are often prescribed to reduce the ability of blood to coagulate and thereby prevent blood clots in individuals with atrial fibrillation. Currently, warfarin is most commonly used, and patients with atrial fibrillation comprise the largest patient group using the drug. The sensitivity of warfarin varies among individuals,
and in the same individual over time, and is influenced, eg, by diet and other drugs.

Warfarin therapy carries a risk for severe and life-threatening haemorrhage. Treatment involves finding a balance between benefits (protection against blood clots and stroke) and risks (side effects such as severe, occasionally life-threatening, haemorrhage). Hence, it is important to appropriately inhibit the blood's ability to coagulate. Consequently, warfarin therapy requires that patients are checked regularly and that dosage is adjusted to maximise protective effects while minimising potential risks for side effects.

Warfarin therapy is managed by analysing prothrombin complex (PC), a service provided in Sweden by special anticoagulation clinics (AC clinics) or primary care. Not every patient with atrial fibrillation and an elevated stroke risk can be treated with warfarin due to the risks or difficulties in managing this complicated treatment.

Dabigatran is a new type of anticoagulant medication with a different mechanism of action; it is a direct thrombin inhibitor.

The target group for dabigatran treatment includes individuals with atrial fibrillation and an elevated risk of stroke, but who do not have heart valve problems. The study in this report included only patients appropriate for warfarin therapy.

Primary questions

In weighing benefits and risks, are there any overall differences between dabigatran treatment and warfarin therapy?

The assessment also aims to compare the costs and cost-effectiveness of dabigatran treatment and warfarin therapy.

Patient benefit

Assuming that the management of warfarin therapy is of good quality, corresponding to standard practice in Swedish health care, the following apply:

- Moderately strong scientific evidence shows no clinically relevant differences in the risk of stroke or systemic embolisation between patients treated with dabigatran and patients treated with warfarin ( وأشارت او).  
- Moderately strong scientific evidence shows no clinically relevant differences in the risk of severe haemorrhage between patients treated with dabigatran and patients treated with warfarin ( وأشارت او).  

Ethical aspects

The report raises a series of potential conflicts of interest and values among patients, taxpayers, corporations, and professions.

Current evidence reveals no general superiority of one treatment over the other at the group level and shows that warfarin therapy is generally the most cost-effective option. However, there may be individual patients for whom warfarin therapy is less appropriate, or completely inappropriate, due to medical reasons. Dabigatran could be a treatment option in such cases. Furthermore, certain individuals may experience comfort- or autonomy-related advantages with dabigatran.

Economic aspects

Since a comparison of centres providing high-quality management of warfarin showed that neither treatment is generally medically superior to the other, we conducted a cost minimisation analysis. Based on the current price of dabigatran, the analysis shows that warfarin therapy is the most cost-effective option. Since the health economic analysis is sensitive to costs associated with visits for specimen taking, dabigatran treatment could be more cost-effective than warfarin therapy in certain individual cases.

Four levels are used in grading the strength of the scientific evidence on which conclusions are based:

- Strong scientific evidence (P rendition P rendition). Based on high or medium quality studies with no factors that weaken the overall assessment.
- Moderately strong scientific evidence (P rendition P). Based on high or medium quality studies with isolated factors that weaken the overall assessment.
- Limited scientific evidence (P rendition P). Based on high or medium quality studies containing factors that weaken the overall assessment.
- Insufficient scientific evidence (P rendition P). Scientific evidence is deemed insufficient when scientific findings are absent, the quality of available studies is low, or studies of similar quality present conflicting findings.
References


Project group
- Magnus von Arbin, MD, Associate Professor, Danderyd Hospital, Stockholm
- Gerd Lärfars, MD, Associate Professor, Södersjukhuset, Stockholm
- Johan Wallin, Project Manager, SBU
- Jan Lillemark, Professor, SBU, lillemark@sbu.se
- SBU Staff: Laura Lintamo, Literature Searcher, Madeleine Lusth Sjöberg, Project Assistant, Lars-Åke Marké, Health Economist

Scientific reviewers
- Bengt Ljungberg, MD, PhD, Medical Products Agency, Uppsala
- Kerstin Hulter Åsberg, MD, Associate Professor, Uppsala University, Uppsala

SBU Alert report no 2011-04
**SBU evaluates healthcare technology**

The Swedish Council on Health Technology Assessment (SBU) is a national governmental agency that assesses healthcare technologies. SBU analyses the benefits, risks, and costs of different methods and compares the scientific facts to prevailing practices in Sweden. SBU’s goal is to provide stronger evidence for everyone engaged in shaping the delivery of health services.

The SBU Alert reports are produced in collaboration with experts from the respective subject areas, the National Board of Health and Welfare, the Medical Products Agency, the Swedish Association of Local Authorities and Regions, and a special advisory panel (the Alert Advisory Board).

This assessment was published in 2011. Findings based on strong scientific evidence usually continue to apply well into the future. However, findings based on insufficient, limited, or contradictory evidence might have already been replaced by more recent findings.

The complete report is available in Swedish.

**The Alert Advisory Board**

Jan-Erik Johansson, Chairman, Professor
Christel Bahtsevani, PhD
Lars Borgquist, Professor
Bo Carlberg, Associate Professor
Jane Carlsson, Professor
Per Carlsson, Professor
Björn-Erik Erlandsson, Professor
Mårten Fernö, Professor
Stefan Jutterdal, Director of Improvement
Viveca Odlind, Professor
Anders Rydh, Associate Professor
Anders Tegnell, PhD
Jan Wahlström, Professor Emeritus
Anna Åberg Wistedt, Professor

**SBU Board Subcommittee**

Susanna Axelsson, David Bergqvist, Håkan Ceder, Tove Livered, Jan Liliemark, Nina Rehnqvist, Måns Rosén, Ewalotte Ränzlöv

Publisher: Måns Rosén, Director, SBU
Graphic Production: Anna Edling, SBU